RHONE-POULENC DRUG STRATEGY INCLUDES "EVENTUAL" U.S. EXPANSION
RHONE-POULENC DRUG STRATEGY INCLUDES "EVENTUAL" U.S. EXPANSION, the French chemical/diversified company reported in a recent filing with the Securities & Exchange Commission covering a planned public offering. "Eventual expansion into key geographical markets such as the U.S. and Japan is . . . targeted, but the cost of entry into these markets is relatively high," the registration statement notes. Rhone-Poulenc observed that it has "historically adopted a policy of licensing, rather than direct sales, of its ethical pharmaceuticals" in the U.S. The company's major product lines are distributed in the U.S. by Searle (Flagyl), SmithKline (prochlorperazine) and American Home Products (Orudis, Sectral and Phenergan). These licensing agreements combined with the recent acquisitions of two bulk pharmaceutical businesses in the U.S., U.S. Ethicals and Purification Engineering, Rhone-Poulenc noted, "give the company a small foothold in the U.S. market." In addition, the French firm already has its own research and registration facility in Mon-mouth Junction, N.J. for "future products." However, before expansion into new markets, Rhone-Poulenc reported that its first priority in the health care area is to "supplement internal growth with selective acquisitions" in geographic therapeutic areas where the company has already established a strong position. Geographically, Rhone-Poulenc cited Europe, Africa and South America. Drug markets with potential for expansion, Rhone-Poulenc said, are infectious diseases, cardiovasculars, anti-rheumatics, vaccines, analgesic bulk chemicals and vitamins. In addition, Rhone-Poulenc said it plans to invest in research to develop new chemical entities and in OTC pharmaceuticals. In 1986, the nonsteroidal anti-inflammatory Orudis (ketaprofen) surpassed Flagyl (metronidazole) as Rhone-Poulenc's topselling Rx product worldwide. The previous year, Flagyl had accounted for 19% of the company's over $1.2 bil. in pharmaceutical sales, or approximately $240 mil. Rhone-Poulenc's other leading Rx product areas in 1985 were the cardiovascular agents, Sermion (nicergoline) and Sectral (acebutolol), which together had worldwide sales of roughly $225 mil., serums and vaccines, with sales of approximately $150 mil., psychotropics, led by Stemetil (prochlorperazine), with sales of about $135 mil., and the anti-infectious agents, Josacine (josamycine) and Rovamycine (spiramycine), with combined 1985 sales of roughly $75 mil. Reflecting Rhone-Poulenc's aggressive acquisition program in recent years, nearly one-third of the company's pharmaceutical business is now being derived from businesses acquired since 1983. That year Rhone-Poulenc acquired the French drug firm Pharmuka, which contributed sales of approximately $120 mil. in 1985. In 1986, Rhone-Poulenc accelerated its acquisition program with four international acquisitions that, combined, generated sales of approximately $280 mil. Rhone-Poulenc's largest drug acquisition in 1986, by far, was the West German firm A. Natterman & Cie GmbH with annual sales over $200 mil. Rhone-Poulenc also made three other drug acquisitions with sales in the $20-$30 mil. range, including Upjohn Brazil, the Italian firm Roger Bellon Schoum S.p.a., and Gerot, based in Austria.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Clarity on what transferable exclusivity vouchers may look like for new antimicrobial drugs could be nearing. Denmark’s new presidency of the Council of the EU has prioritized concluding its negotiations with European Parliament over the legislative overhaul of the EU’s pharmaceutical legislation.
After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.
Bayesian statistics could help clinical trial sponsors to include external information in their analyses, but concerns around bias and incorrect conclusions remain, the European Medicines Agency said.